Delving into the Latest Updates on Quinagolide Hydrochloride with Synapse

A Randomised, Double-blind, Placebo-controlled, Proof-of-mechanism Phase 2 Trial Investigating the Effect of Quinagolide Extended-release Vaginal Ring on Reduction of Lesions Assessed by High-resolution Magnetic Resonance Imaging in Women With Endometrioma, Deep Infiltrating Endometriosis, and/or Adenomyosis

This will be a randomized, double-blind, placebo-controlled, proof-of-mechanism phase 2 trial investigating the effect of quinagolide extended-release vaginal ring on reduction of lesions assessed by high-resolution magnetic resonance imaging in women with endometrioma, deep infiltrating endometriosis, and/or adenomyosis.

Start Date19 Aug 2019

Sponsor / Collaborator

Ferring Pharmaceuticals A/S

NCT03692403 / CompletedPhase 2

A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial Assessing the Efficacy, Safety and Dose-response of Quinagolide Extended-release Vaginal Rings Administered Sequentially for 4 Menstrual Cycles in Women With Moderate to Severe Endometriosis-related Pain

To evaluate the efficacy of three doses of quinagolide administered as an extended-release vaginal ring compared to placebo on reduction of moderate to severe endometriosis-related pain

Start Date26 Dec 2018

Sponsor / Collaborator

Ferring Pharmaceuticals A/S

EUCTR2012-001789-13-ES / Unknown statusNot Applicable

Double-blind, randomized, controlled contraceptives, parallel group, to assess the effect on nerve fibers in patients diagnosed with endometriosis grade III / IV symptomatic ascending-dose oral quinagolide for 16 weeks

Start Date16 Nov 2012

Sponsor / Collaborator-

100 Clinical Results associated with Quinagolide Hydrochloride

Login to view more data

100 Translational Medicine associated with Quinagolide Hydrochloride

Login to view more data

100 Patents (Medical) associated with Quinagolide Hydrochloride

Login to view more data

204

Literatures (Medical) associated with Quinagolide Hydrochloride

16 Feb 2024·The Journal of Organic Chemistry

Streamlined Stereoselective Entry to (−)-Quinagolide and to 3-Substituted Octahydrobenzo[g]-Quinolines

Article

Author: Pineschi, Mauro ; Ryberg, Per ; Comparini, Lucrezia Margherita ; Favero, Lucilla ; Di Pietro, Sebastiano ; Sardelli, Francesca

A very short stereoselective synthesis of enantiomerically pure (3S, 4aS, 10aR)-quinagolide has been developed. The key steps involved are a copper-catalyzed regioselective arylation of (S)-epichlorohydrin with 1,6-dimethoxynaphthalene and a diastereoselective trans-reduction of a cyclic enamine intermediate. The possibility to use both enantiomers of epichlorohydrin and the diastereodivergency found in the reduction process paves the way for a general preparation also in the nonracemic form of chiral trans-fused 3-substituted octahydrobenzo[g]quinolines that are privileged structures in medicinal chemistry.

01 Jan 2023·Frontiers in pharmacology

Research advances in drug therapy of endometriosis.

Review

Author: Shi, Jianyou ; Guo, Chun ; Zhuo, Yuan ; Wang, Lin ; Tan, Xin ; Zheng, Wei ; Chen, Lu ; Jiang, Zhongliang ; Yu, Dongke ; Banda, Srikanth ; Feng, Guimei

Endometriosis is one of the most common benign gynecological disorders in reproductive-aged women. The major symptoms are chronic pelvic pain and infertility. Despite its profound impact on women's health and quality of life, its pathogenesis has not been fully elucidated, it cannot be cured and the long-term use of drugs yields severe side effects and hinders fertility. This review aims to present the advances in pathogenesis and the newly reported lead compounds and drugs managing endometriosis. This paper investigated Genetic changes, estrogen-dependent inflammation induction, progesterone resistance, imbalance in proliferation and apoptosis, angiogenesis, lymphangiogenesis and neurogenesis, and tissue remodeling in its pathogenesis; and explored the pharmacological mechanisms, constitutive relationships, and application prospects of each compound in the text. To date, Resveratrol, Bay1316957, and bardoxifene were effective against lesions and pain in controlled animal studies. In clinical trials, Quinagolide showed no statistical difference with the placebo group; the results of phase II clinical trial of the IL-33 antibody have not been announced yet; clinical trial stage III of vilaprisan was suspended due to drug toxicity. Elagolix was approved for the treatment of endometriosis-related pain, but clinical studies of Elagolix for the pretreatment of patients with endometriosis to before In vitro fertilization treatment have not been fulfilled. The results of a clinical study of Linzagolix in patients with moderate to severe endometriosis-related pain have not been disclosed yet. Letrozole improved the fertility of patients with mild endometriosis. For endometriosis patients with infertility, oral GnRH antagonists and aromatase inhibitors are promising drugs, especially Elagolix and Letrozole.

02 Nov 2022·Gynecological Endocrinology

State of the art, new treatment strategies, and emerging drugs for non-hormonal treatment of endometriosis: a systematic review of randomized control trials

Review

Author: Puževski, Tomislav ; D’alterio, Maurizio Nicola ; Zajec, Vendy ; Herman, Mislav ; Ciebiera, Michał ; Vitale, Salvatore Giovanni ; Angioni, Stefano ; Carugno, Jose ; Ćorić, Mario ; Mikuš, Mislav

Objective: The aim of this systematic review is to recap the data obtained from randomized controlled trials looking at new pharmacologic treatments for endometriosis published over the last decade with a focus on non-hormonal therapeutic options alleviating endometriosis-associated pelvic pain.Methods: We identified relevant original studies in the English language through a search of the MEDLINE, Scopus, and EMBASE (2012 to present) databases using the appropriate MeSH terms and applying the article type filter 'randomized controlled trials'. A total of 179 records were found during the electronic search. After a detailed evaluation and review of the manuscripts, seven primary articles met the inclusion criteria. A systematic review of the data was conducted.Results: This review included several, non-hormonal emerging drug therapies for endometriosis-associated pelvic pain. Based on our results, we divided well-founded studies into three subgroups: antiangiogenic agents, immunomodulators, and natural components. Randomized control trials showed promising results with dopamine agonists (cabergoline, quinagolide, and bromocriptine), and the immunomodulatory JNK inhibitor bentamapimod. Agents that have not been represented in randomized control trials or have failed to demonstrate efficacy include statins and TNF-α inhibitors.Conclusion: Although there are substantial improvements in non-hormonal therapy options, majority of the currently available treatment options are supressive rather than curative and do not present a final solution for patients. Future research priorities should be to identify novel target therapies and to evalute the effects of available drugs through different routes of administration.

100 Deals associated with Quinagolide Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Quinagolide Hydrochloride	G02CB04	DB09097

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hyperprolactinemia	ZA	Novartis AG	24 Sep 1997

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Endometriosis	Phase 1	DK	Ferring BV	21 Jun 2019
Endometriosis	Phase 1	DE	Ferring BV	21 Jun 2019
Pain	Phase 1	US	Ferring BV	28 Nov 2018
Ovarian Hyperstimulation Syndrome	Phase 1	ES	Ferring BV	01 Jun 2006
Adenomyosis	Preclinical	IT	Ferring Pharmaceuticals A/S	19 Aug 2019
Adenomyosis	Discovery	DK	Ferring Pharmaceuticals A/S	19 Aug 2019
Adenomyosis	Discovery	PL	Ferring Pharmaceuticals A/S	19 Aug 2019
Endometriosis	Discovery	PL	Ferring BV	21 Jun 2019
Endometriosis	Discovery	IT	Ferring BV	21 Jun 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03749109 (CTgov)	Phase 2	Adenomyosis \| Endometriosis	67	Quinagolide 1080 µg (Quinagolide 1080 µg)	(vajozpwxqj): Difference in LS mean = 1.74 (95.0% CI, -10.45 to 13.94); Difference in LS mean = 3.35 (95.0% CI, -2.89 to 9.59); Difference in LS mean = 0.33 (95.0% CI, -10.33 to 10.99) View more	-	07 Sep 2022
NCT03749109 (CTgov)	Phase 2	Adenomyosis \| Endometriosis	67	Placebo (Placebo)		-	07 Sep 2022
Pubmed \| Fertil Steril	Not Applicable	Hyperprolactinemia	9	Quinagolide	flogiculct(hcjhcikchf) = vwaeeijedy ofmjbgecrn (jwhhbjzlnn )	-	01 Mar 2011